Argentine hemorrhagic fever vaccines

Area of Science:

• Virology
• Public Health
• Vaccinology

Background:

• Argentine hemorrhagic fever (AHF) is an acute disease caused by Junin virus (JUNV).
• The natural reservoir for JUNV is the rodent Calomys musculinus, with human infection occurring through contact with infected rodents.
• AHF has been a significant public health issue in Argentina since the 1950s, with a steady expansion of its endemic area.

Purpose of the Study:

• To review advancements in the diagnosis and treatment of AHF.
• To discuss the development of vaccines against AHF and other arenaviral diseases.
• To provide updated information on the Candid #1 vaccine's characteristics and field performance.

Main Methods:

• Review of research strategies for anti-AHF and anti-arenaviral vaccines.
• Analysis of diagnostic and therapeutic measure improvements.
• Evaluation of the Candid #1 vaccine's development, manufacturing, and regulatory approval.

Main Results:

• Significant progress has been made in etiological diagnosis and therapeutic interventions for AHF.
• The Candid #1 vaccine, a live attenuated vaccine, has been developed and is currently used to prevent AHF.
• Candid #1 is the first vaccine to control an arenaviral hemorrhagic fever and the first live viral vaccine manufactured and registered in Argentina.

Conclusions:

• The Candid #1 vaccine represents a major achievement in controlling arenaviral hemorrhagic fevers.
• International collaboration and governmental commitment were crucial for the vaccine's development and accessibility.
• The vaccine's successful registration and distribution highlight advancements in Argentina's pharmaceutical manufacturing and regulatory capabilities.